Predictive value of serum CA-125 levels in patients with persistent or recurrent epithelial ovarian cancer or peritoneal cancer treated with bevacizumab on a Gynecologic Oncology Group phase II trial

✍ Scribed by Leslie M. Randall; Michael W. Sill; Robert A. Burger; Bradley J. Monk; Barbara Buening; Joel I. Sorosky

• Book ID: 113963542
• Publisher: Elsevier Science
• Year: 2012
• Tongue: English
• Weight: 484 KB
• Volume: 124
• Category: Article
• ISSN: 0090-8258
• DOI: 10.1016/j.ygyno.2011.11.035